TNF and metabolic syndrome: The administration of Lactobacillus reuteri V3401 to obese adults aged 18 to 65 years who had been experiencing metabolic syndrome for 12 weeks was accompanied by lower levels of inflammation biomarkers, such as TNF-α, IL-6, IL-8, and soluble intercellular adhesion molecule-1, thereby reducing the risk of cardiovascular diseases [72].